

Evaluation of *Terminalia chebula* Extract for Anti-Arthritic Efficacy and Safety in Osteoarthritic Dogs

Nichole Murdock¹, Ramesh Gupta C^{1*}, Natalia Vega¹, Katie Kotora¹, Jean Miller¹, John Goad T¹, Michelle Lasher A¹, Terry Canerdy D¹ and Sanyasi R Kalidindi²

¹Murray State University, Murray/Hopkinsville, KY, USA

²Natreon Inc, New Brunswick, NJ, USA

*Corresponding author: Ramesh Gupta C, Murray State University, Murray/Hopkinsville, Breathitt Veterinary Center, Toxicology Department, P.O. Box 2000; 715 North Drive, Hopkinsville, KY 42240-2000, USA, Tel: (270) 886-3959; Tel: (270) 886-4295; E-mail: rgupta@murraystate.edu

Rec date: Dec 17, 2015; Acc date: Jan 18, 2016; Pub date: Jan 20, 2016

Copyright: © 2016 Murdock N, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

The present investigation was undertaken to assess anti-inflammatory and anti-arthritic efficacy and safety of *T. chebula* extract (TCE) in moderately osteoarthritic (OA) dogs. Dogs with OA received either 500 mg placebo or 500 mg TCE twice daily for 150 days. On a monthly basis, dogs were given a full physical exam and were evaluated for arthritic pain (overall pain, pain upon limb manipulation, and pain after physical exertion), inflammation (erythrocyte sedimentation rate, ESR), and analysis of complete blood count (CBC) and serum biomarkers of liver (bilirubin, ALT, and AST), kidney (BUN and creatinine), and heart and skeletal muscle (CK) functions. Elbow and stifle joints were radiographed on day 0 and day 150 for evaluation of arthritic progression. Dogs given TCE showed significant ($P < 0.01$) reductions in overall pain, pain upon limb manipulation, and pain after physical exertion by day 90, with maximum effects on day 150 (81.2%, 81.5%, and 84.2%, respectively). A marked reduction in ESR coincided with pain reduction in TCE-treated dogs, which was indicative of anti-inflammatory effect of TCE. Radiographic evidence also indicated slowed progression of OA in joints examined. No significant change occurred in physical parameters, CBC parameters, or serum biomarkers in dogs on placebo or treatment, which suggested that TCE was well tolerated. It can be concluded that TCE, by having many active principles (chebulagic acid, chebulinic acid, corilagin, hydrolysable tannoids, etc.) might have provided antioxidant, anti-inflammatory and anti-arthritic effects in dogs without causing any side effects.

Keywords: *Terminalia chebula* extract; Nutraceutical; Canine Osteoarthritis; Antioxidant; Anti-inflammatory; Anti-arthritic; Dietary supplement

Introduction

Osteoarthritis (OA) is a debilitating, degenerative, and painful inflammatory disease that affects the synovial joints, and is highly prevalent in dogs [1,2]. Currently, more than 20% of the adult and 80% of the geriatric dog population in the US (>80 million) suffer from OA [3]. A number of factors (injury/trauma, aging, excessive or lack of exercise, genetic predisposition, poor nutrition, obesity, and environmental factors) can contribute to OA in dogs [4-8]. Often, large breed dogs (German Shepherds, Labrador Retrievers, Siberian Huskies, Rottweilers, and others) are prone to develop OA (>45%) as compared to smaller breeds [9,10]. Common clinical signs of OA include limping, immobility, stiffness of joints, crepitus, periarticular swelling, and pain upon manipulation of the joint and lameness [3,11-17].

Pathophysiology of OA is complex and it needs a brief discussion before selection of disease modifying anti-osteoarthritic agents [12,18-21]. OA is a chronic inflammatory joint disease that slowly progresses and causes degeneration of the cartilage, hypertrophy of bone at the margins, and changes in the synovial membrane that eventually results in pain and stiffness of joints. Cells in damaged joints release cytokines (IL-1 β and IL-6), tumor necrosis factor- α (TNF- α), followed by stimulation of mitogen activated protein kinase (MAPK), matrix metalloproteinases (MMP-1, MMP-3, and MMP-13), inducible

nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), phospholipase 2A, nitric oxide (NO), prostaglandin E2 (PGE2), and platelet activating factor (PAF). These cascading events and many others cause inflammation, subchondral bone thickening, breakdown of proteoglycans and destruction of cartilage [19,22-29].

In a clinical setting, veterinarians make a diagnosis of OA in dogs based upon physical examination and radiographic evidence [2,13,16,20,29,30]. CT scan and/or MRI findings reveal changes of the joint and cartilage degeneration, which are consistent with OA, but are limited to humans and experimental studies [31-33].

Currently, the management of OA in dogs is usually aimed at minimizing joint pain by reducing inflammation, slowing the progression of cartilage degeneration and improving cartilage repair, thereby increasing the joint's flexibility and quality of life of the animal [17,20,29,34,35]. Currently, veterinarians have many options for managing the signs and symptoms of OA, including pharmaceuticals, nutraceuticals, nutrition, surgery, gene therapy, stem cell therapy, laser therapy, physical therapy, and acupuncture [9,15,29,34,36-41]. To alleviate OA associated inflammation and pain, veterinarians often use nonsteroidal anti-inflammatory drugs (NSAIDs), such as carprofen (Rimadyl), meloxicam (Metacam), firocoxib (Previcox), etc., [42,43]. Most NSAIDs inhibit the activity of the COX enzymes (COX-1 and COX-2) that produce prostaglandins [44], which are important factors for the pathogenesis of inflammation, swelling, pain and fever [42,45,46]. NSAIDs eliminate pain, but do not eliminate signs and symptoms of active disease, nor do they repair cartilage. Furthermore, the use of NSAIDs can be linked to side effects, such as hepatic and

renal dysfunction [47-49] reduced appetite, vomiting, and gastrointestinal upset and bleeding [50-54]. Additionally, NSAIDs have been reported to inhibit bone healing [55]. Recently, Lees et al. [56] indicated that mavacoxib (Trocoxil, a selective COX-2 inhibitor) can be an alternative to NSAIDs that indiscriminately inhibit both COX-1 and COX-2. Of course, the use of mavacoxib also has limitations with regard to dog weight (contraindicated in dogs weighing <5 kg) and duration of treatment (not for >6.5 months).

Under these circumstances, the long-term use of safe modalities is warranted. Presently, veterinarians commonly choose nutraceuticals to manage the signs and symptoms of OA in dogs [57,58]. In the past two decades, among all nutraceuticals, glucosamine and chondroitin sulfate have been predominantly used in the treatment of canine OA [13,58-61]. In clinical trials, nutraceuticals such as glucosamine and chondroitin sulfate and/or undenatured type II collagen [13,60-62] Crominex® -3+ [16] purified shilajit [30], avocado/soybean unsaponifiables [63], green lipped mussel [35,64] and curcumin [65] have been found significantly effective in ameliorating OA pain and have shown to be safe for long-term use in canines.

Terminalia chebula Retzius (*T. chebula* Retz. Combretaceae), commonly known as Black Myrobalan or Harad (mentioned as "King of medicines" in Ayurvedic Materia Medica), is known to contain several bioactive constituents that exert a variety of pharmacological actions [66]. The present investigation was undertaken to evaluate the anti-inflammatory and anti-arthritic effects of TCE and its safety in moderately osteoarthritic dogs.

Material and Methods

Experimental design

Animal selection (inclusion/exclusion) criteria: Ten client-owned arthritic dogs (each weighting between 40-60 pounds) were selected for the present investigation based on the signs of arthritis (joint stiffness, lameness, and pain at the level of moderate severity) and radiographic evidence. Any arthritic dog having any other serious disease or complications related to hepatic, renal, or cardiovascular systems, or tumor/cancer, was not included in the study. Any dog infested with intestinal parasites (*Giardia* or *Cryptosporidium*) was also excluded. Throughout the study, dogs remained with their owners. Before initiation of any experiments, IACUC approval and owners consents were obtained.

Animal treatment: Standardized *T. chebula* aqueous extract (AyuFlex) 500 mg capsules and Placebo capsules were supplied by Natreon, Inc., New Brunswick, NJ, USA. In Group-I, five dogs received placebo (500 mg twice daily); and in Group-II, five dogs received *T. Chebula* extract (500 mg twice daily; one capsule 1 h before morning meal, and one capsule 1 h before evening meal) for a period of 150 days. None of the dogs received any other treatment for a period of 3 to 4 weeks before or during the study period. The study was conducted double-blinded, that is the investigators or dog owners had no knowledge of the content(s) of white colored capsules.

Physical examination: On a monthly basis, dogs were evaluated for physical parameters, including body weight (kg) using a digital scale, heart rate (beats/min) using a stethoscope, and rectal temperature (°F) using a thermometer. Respiration rate was auscultated and recorded using a stethoscope; however, some dogs could not be evaluated due to

excessive panting, and therefore data could not be statistically analyzed and are not included in this paper.

Pain measurement criteria: On a monthly basis, each dog was evaluated for arthritis associated pain (overall pain, pain upon limb manipulation, and pain after physical exertion) for a period of five months, using a Glasgow scoring system. In brief, overall pain, on a scale of 0-10, was graded as: 0, no pain; 2.5, mild pain; 5, moderate pain; 7.5, severe pain; and 10, severe and constant pain. Overall pain was measured on a scale of 0-10 because it provides a broad range for inclusion of daily activity. Pain after limb manipulation, on a scale of 0-4, was graded as: 0, no pain; 1, mild pain; 2, moderate pain; 3, severe pain; and 4, severe and constant pain. Pain after physical exertion, on a scale of 0-4, was graded as: 0, no pain; 1, mild pain; 2, moderate pain; 3, severe pain; and 4, severe and constant pain. Examination of each limb started with forelimbs and ended with rear limbs. The evaluation was focused on manipulation of the limbs in a forward, backward, and circular motion. The three main joints commonly evaluated were shoulder joint, knee joint, and stifle joint. Each dog was also evaluated for popping and cracking of the joint (crepitus) as well as vocalization due to pain. The present investigation was carried out on moderately arthritic dogs. A dog was considered moderately arthritic when exhibiting overall pain of about 5 on the scale of 0-10; pain after limb manipulation about 2 on the scale of 0-4; and pain after physical exertion about 2 on the scale of 0-4. Details of pain measurement criteria by observations have been described in our previous publications [13,16,30,62].

Radiographic evaluation: Arthritic joints (elbow and stifle) were evaluated radiographically using a DUOCON 1 VIDEX MACHLETT (125 KVP) equipped with digital imaging software on day 0 and day 150.

Liver, kidney, heart and skeletal muscle functions: On a monthly basis, blood samples were collected in serum separator tubes from jugular vein or cephalic vein. Serum samples were assayed for liver (bilirubin, ALT, and AST), kidney (BUN and creatinine) and heart and skeletal muscle (CK) functions, using a Beckman AU480 Chem Serum Analyzer (Irving, TX, USA).

Blood analysis for complete blood count (CBC) and erythrocyte sedimentation rate (ESR): On a monthly basis, blood samples were collected in EDTA tubes from jugular vein or cephalic vein, and assayed for complete blood count (CBC) with white cell differential, using the Sysmex XT 2000iV system (Mundelein, IL, USA). Blood samples were also assayed for erythrocyte sedimentation rate (ESR) using a Sedi-Rate™ ESR System to measure the level of inflammation.

Statistical analysis: Data were statistically analyzed for Mean ± SEM and Analysis of Variance (ANOVA) coupled with Tukey-Kramer multiple comparison test for significance (Alpha=0.05) using NCSS9 software.

Results

Data presented in Table 1 show the results of body weight, heart rate and body temperature of dogs receiving placebo and *T. chebula* extract (TCE). At no time point did dogs in either group show a significant difference in body weight, heart rate, or body temperature, compared to day 0 (P>0.05).

Parameter	Control/ Treated	Day 0	Day 30	Day 60	Day 90	Day 120	Day 150
Body weight (kg)	Control	28.49 ± 1.48	28.59 ± 1.60	27.66 ± 1.78	28.76 ± 1.35	28.14 ± 1.49	28.39 ± 1.31
	Treated	24.20 ± 2.05	24.24 ± 2.28	24.86 ± 1.95	24.91 ± 1.81	23.99 ± 2.28	23.90 ± 2.71
Heart beat (Beats/ min)	Control	121.6 ± 10.48	114.8 ± 5.20	122.4 ± 6.76	131.6 ± 6.58	122.4 ± 4.66	122.4 ± 6.88
	Treated	131.2 ± 11.27	126.4 ± 7.86	128.8 ± 7.94	130.4 ± 3.25	125.0 ± 5.51	139.0 ± 10.75
Body temperature (°F)	Control	101.76 ± 0.36	101.10 ± 0.18	101.44 ± 0.29	101.14 ± 0.16	101.40 ± 0.33	101.14 ± 0.15
	Treated	101.12 ± 0.45	101.5 ± 0.23	100.92 ± 0.20	101.06 ± 0.30	101.68 ± 0.23	101.63 ± 0.38

Table 1: Effects of placebo or *T. chebula* extract on physical parameters in arthritic dogs. No statistically significant difference from day 0 ($P>0.05$).




Figure 1: Effects of placebo or *T. chebula* Extract on overall pain in arthritic dogs. Values significantly different from day 0 ($P<0.05$).

Figure 1 shows the results of overall pain in dogs receiving placebo (Group I) or TCE (Group II). Dogs on placebo exhibited no significant change in pain level as compared to day 0 ($P>0.05$). Overall pain in dogs receiving TCE was significantly ($P<0.05$) reduced by day 90 (2.50 ± 0.50) as compared to day 0 (6.00 ± 0.35). The pain level was maximally reduced (1.13 ± 0.38) on day 150 (81.2%).

Figure 2 presents the pain level after limb manipulation in dogs receiving placebo or TCE. Dogs on placebo exhibited no significant change in pain at any time compared with day 0 ($P>0.05$). TCE-treated dogs showed significant reduction in pain upon limb manipulation by day 90 (1.10 ± 0.33) compared to day 0 (2.70 ± 0.2). The maximum pain reduction (0.5 ± 0.20) was observed on day 150 (81.5%).

Data in Figure 3 present pain after physical exertion in dogs receiving placebo or TCE for a period of 150 days. Dogs on placebo showed no significant reduction in pain at any time point compared to day 0. TCE-treated dogs exhibited significant reduction in pain on day 90 (1.20 ± 0.34) compared to day 0 (2.50 ± 0.19). Maximal pain reduction (0.38 ± 0.13) was noted on day 150 (84.2%).




Figure 2: Effects of placebo or *T. chebula* Extract on pain upon limb manipulation in arthritic dogs. *Values significantly different from day 0 ($P<0.05$).




Figure 3: Effects of placebo or *T. chebula* extract on pain after physical exertion in arthritic dogs. Values significantly different from day 0 ($P<0.05$).

Data of erythrocyte sedimentation rate (ESR) in dogs receiving placebo or TCE are shown in Table 2. No significant reduction in ESR was noted at any time point in dogs on placebo. Dogs receiving TCE

showed significant ($P < 0.05$) reduction in ESR on day 120 (0.63 ± 0.47) with a maximum reduction on day 150 (0.38 ± 0.38) compared to day 0 (2.40 ± 0.68), suggesting a marked reduction in inflammation.

Left stifle of a dog on placebo show exostosis involving the distal femur, proximal tibia, and patella (Figure 4). The radiographic changes noted are more severe in the radiograph taken on Day 150, which

validates the normal progression of OA in the placebo group. Radiographically, the left stifle demonstrates how the body is attempting to stabilize an unstable joint by the process of bone formation. This is the normal disease progression of OA clinically as an animal attempts to make use of the joint.

Parameter	Control/Treated	Day 0	Day 30	Day 60	Day 90	Day 120	Day 150
ESR	Control	4.00 ± 2.01	3.80 ± 2.60	4.30 ± 2.43	4.30 ± 2.68	7.20 ± 5.70	5.20 ± 3.45
	Treated	2.40 ± 0.68	2.00 ± 0.32	1.20 ± 0.37	1.30 ± 0.77	0.63 ± 0.47*	0.38 ± 0.38*

Table 2: Effects of placebo or *T. chebula* extract on erythrocyte sedimentation rate (ESR) in arthritic dogs. *Values significantly different from day 0 ($P < 0.05$).




Figure 4: Radiographs of the left stifle of a dog on placebo has exostosis involving the distal femur, proximal tibia, and patella.

Radiographs obtained of the right humero-radial (elbow) joint from a dog receiving TCE showed a slowed progression of bone formation in a typical arthritic joint (Figure 5). The amount of exostosis involving the distal humerus, radius, and ulna is not what one would expect to observe in a 150 day interval. Minor radiographic sclerosis of the articular surfaces is observed. The comparison of the Day 1 versus Day 150 radiographs show some arthritic progression, but at a much slower pace than is typical in an OA joint.




Figure 5: Radiographs obtained of the right humero-radial (elbow) joint from a dog receiving TCE showed a slowed progression of bone formation in a typical arthritic joint.

Serum chemistry and CBC data of dogs treated with placebo or TCE are presented in Tables 3 and 4, respectively. Neither placebo nor TCE treated dogs showed a statistically significant difference from Day 0 for any serum chemistry or CBC parameters ($P > 0.5$). One participant had consistently increased levels in RBC, HGB, and HCT. This was likely due to a difficult blood collection.

Parameter	Control/ Treated	Day 0	Day 30	Day 60	Day 90	Day 120	Day 150
Total Bilirubin (mg/dl)	Control	0.22 ± 0.02	0.18 ± 0.05	0.16 ± 0.02	0.14 ± 0.02	0.18 ± 0.02	0.18 ± 0.02
	Treated	0.16 ± 0.02	0.20 ± 0.04	0.18 ± 0.04	0.26 ± 0.04	0.20 ± 0.00	0.20 ± 0.04
ALT/(IU/L)	Control	84.20 ± 29.19	87.20 ± 33.38	88.60 ± 29.86	80.20 ± 23.81	71.60 ± 20.14	76.40 ± 26.12
	Treated	59.20 ± 10.37	42.80 ± 8.89	50.00 ± 9.41	223.80 ± 173.90	45.25 ± 8.82	35.75 ± 6.02
AST(IU/L)	Control	27.80 ± 2.78	25.20 ± 2.48	22.00 ± 1.64	25.80 ± 1.88	31.00 ± 6.41	24.00 ± 2.85
	Treated	26.40 ± 2.42	26.60 ± 1.03	28.40 ± 1.60	56.20 ± 31.28	23.25 ± 1.75	25.75 ± 2.39
BUN(mg/dL)	Control	18.80 ± 2.94	20.00 ± 3.15	17.60 ± 1.08	18.80 ± 1.88	17.00 ± 0.89	20.60 ± 2.27

	Treated	13.40 ± 1.83	12.20 ± 1.43	14.00 ± 1.05	15.40 ± 3.20	14.75 ± 2.81	13.00 ± 2.94
Creatinine (mg/dL)	Control	0.93 ± 0.08	1.00 ± 0.07	0.99 ± 0.07	1.00 ± 0.08	1.00 ± 0.08	1.00 ± 0.06
	Treated	0.89 ± 0.09	0.85 ± 0.07	0.88 ± 0.07	0.85 ± 0.10	0.86 ± 0.05	0.88 ± 0.08
CK (IU/L)	Control	116.20 ± 21.77	96.60 ± 12.23	88.20 ± 11.40	138.00 ± 39.54	325.80 ± 171.67	135.60 ± 39.17
	Treated	133.00 ± 28.09	3.80 ± 2.60	4.30 ± 2.43	4.30 ± 2.68	7.20 ± 5.70	5.20 ± 3.45

Table 3: Effects of placebo or *T. chebula* extract on serum chemistry parameters in arthritic dogs. No statistically significant difference from day 0 ($P > 0.05$).

Parameter	Control/ Treated	Day 0	Day 30	Day 60	Day 90	Day 120	Day 150
RBC (106/ μ L)	Control	6.77 ± 0.32	7.03 ± 0.24	6.84 ± 0.16	6.78 ± 0.16	6.93 ± 0.28	6.75 ± 0.09
	Treated	8.19 ± 0.02	7.89 ± 0.41	7.96 ± 0.44	8.04 ± 0.30	8.37 ± 0.27	7.91 ± 0.19
WBC (103/ μ L)	Control	7.61 ± 0.80	8.11 ± 0.73	7.97 ± 0.84	8.47 ± 0.79	8.54 ± 0.78	9.37 ± 0.81
	Treated	8.55 ± 1.29	8.77 ± 1.50	8.87 ± 1.21	9.03 ± 1.02	9.89 ± 0.76	9.68 ± 1.48
HGB(g/dL)	Control	16.74 ± 0.55	16.86 ± 0.74	16.50 ± 0.66	16.58 ± 0.74	16.78 ± 0.96	16.64 ± 0.60
	Treated	19.04 ± 0.47	18.46 ± 0.88	16.50 ± 0.66	16.58 ± 0.74	16.78 ± 0.96	16.64 ± 0.60
HCT (%)	Control	52.26 ± 0.61	50.46 ± 1.67	18.78 ± 1.02	19.54 ± 0.77	19.75 ± 0.58	18.65 ± 0.30
	Treated	58.22 ± 2.49	54.30 ± 2.56	55.60 ± 2.74	54.74 ± 1.77	56.53 ± 1.94	54.73 ± 1.75
MCV (fL)	Control	74.14 ± 1.82	71.80 ± 1.46	71.94 ± 1.14	70.30 ± 1.13	72.86 ± 0.88	72.56 ± 1.77
	Treated	71.08 ± 2.32	68.94 ± 0.89	69.52 ± 1.13	68.24 ± 1.48	67.55 ± 1.39	69.23 ± 1.76
MCH (pg)	Control	23.68 ± 0.42	23.94 ± 0.50	24.12 ± 0.59	24.40 ± 0.57	24.14 ± 0.52	24.62 ± 0.58
	Treated	23.26 ± 0.35	23.42 ± 0.32	23.60 ± 0.30	24.32 ± 0.62	23.65 ± 0.41	23.60 ± 0.40
MCHC (g/dL)	Control	32.02 ± 0.91	33.36 ± 0.49	33.50 ± 0.44	34.76 ± 0.67	33.10 ± 0.38	34.00 ± 0.96
	Treated	32.82 ± 0.93	34.02 ± 0.07	33.98 ± 0.32	35.68 ± 0.50	34.98 ± 0.33	34.15 ± 0.63

Table 4: Effects of placebo or *T. chebula* extract on cbc parameters in arthritic dogs. No statistically significant difference from day 0 ($P > 0.05$).

Discussion

The present investigation was carried out with a hypothesis that daily oral administration of *Terminalia chebula* extract (TCE, 1000 mg in two divided doses) in moderately OA dogs will ameliorate the signs of OA and TCE will be well tolerated. Some of the highlighted findings of the present investigation are mentioned here in brief. It was noteworthy from Figures 1-3 that TCE significantly ($P < 0.05$) reduced OA associated pain (81-84%) in dogs, using different criteria (overall pain, pain upon limb manipulation, and pain after physical exertion). TCE-treated dogs had markedly reduced erythrocyte sedimentation rate (ESR), a biomarker of inflammation, suggesting a decline in inflammation (Table 2). Interestingly, timing of reduction in ESR/ inflammation coincided with a decline in arthritic pain. The levels of arthritic pain and ESR remained the same or slightly elevated in dogs receiving placebo. Radiographic evidence suggested that dogs treated with TCE for 150 days exhibited a very slow pace of arthritic progression compared to those receiving placebo (Figures 4 and 6, respectively). Dogs receiving placebo or TCE did not experience any untoward effects, and no significant change occurred in serum markers

or CBC during the period of this investigation, which suggested that TCE was well tolerated.

Dogs with OA may show clinical signs of limping, stiffness of joints, immobility, crepitus, periarticular swelling, and lameness. Pain associated with inflammation appears to be the most serious sign of OA [3,11-16,30]. As stated in the introduction, pathophysiology of OA is very complex due to involvement of multiple factors [18,20-26]. Among all these factors, oxidative stress (due to excess generation of free radicals) and inflammation are proven to be the major contributing factors in joint damage and pain [67-71].

TCE consists of many biologically active principles (chebulagic acid, chebulinic acid, chebulic acid, gallic acid, ellagic acid, tannic acid, corilagin, polyphenolic compounds, triterpenoids, and ascorbate). Chebulagic acid and chebulinic acid are the major constituents and their chemical structures are shown in Figure 6. In experimental and human studies, TCE and its components have been shown to exert antioxidant, anti-inflammatory and analgesic activities, thereby exerting anti-arthritic effects [72-82]. Das et al. [83] demonstrated that

gallic acid in TCE inhibited NF- κ B activity, suggesting its potential for anti-inflammatory activity. In another study, Reddy et al. [84] have shown that chebulagic acid exerts anti-inflammatory and anti-proliferative actions by inhibiting activities of COX2 and 5-lipoxygenase (5-LOX), the key enzymes involved in inflammation. In a recent study, Martinez et al. (2015) reported that a C-phycoyanin-based nutraceutical may provide anti-inflammatory activity by inhibiting COX (preferentially COX-2) and LOX activities. Findings of these investigations corroborated with observations of the present study, supporting TCE-induced antioxidant, anti-inflammatory and anti-arthritic properties in OA dogs. It is highly probable that the observed anti-inflammatory effect was exerted by the active principles (chebulagic acid, gallic acid, polyphenols and other bio-active compounds) present in TCE.




Figure 6: Chemical structures of chebulagic acid and chebulinic acid.

Additional properties of TCE, such as nutritional, physiological [85], adaptogenic, immunomodulatory [86-88], and other pharmacological actions [66,78,79,83,89-93] might have played roles in the treatment of arthritic dogs. In our recent investigations, nutraceuticals such as purified Shilajit and Crominex 3+, by having antioxidant and anti-inflammatory properties, also significantly ameliorated pain and other signs of OA in dogs [16,30].

In conclusion, significant reductions in pain and inflammation, and improvement in joint cartilage and daily activity in dogs treated with TCE might be due to the effects of several pharmacologically active compounds exerting multiple mechanisms, including anti-oxidant and free radical scavenging, anti-inflammatory, anti-proliferative, immunomodulatory, and cytoprotective activities. TCE has a great potential for treatment of OA and has been found to be safe for long-term use. Detailed mechanistic studies need to be explored, and long-term large scale clinical trials in OA prone species (canine, equine, and humans) need to be pursued.

Acknowledgement

This investigation was supported in part by Natreon, Inc (New Brunswick, NJ, USA).

References

1. Paster ER, LaFond E, Biery DN, Iriye A, Gregor TP, et al. (2005) Estimates of prevalence of hip dysplasia in Golden Retrievers and Rottweilers and the influence of bias on published prevalence figures. *J Am Vet Med Assoc* 226: 387-392.

2. Smith GK, Paster ER, Powers MY, Lawler DE, Biery DN, et al. (2006) Lifelong diet restriction and radiographic evidence of osteoarthritis of the hip joint in dogs. *J Am Vet Med Assoc* 229: 690-693.
3. Riialand P, Bichot S, Moreau M, Guillot M, Lussier B, et al. (2012) Clinical validity of outcome pain measures in naturally occurring canine osteoarthritis. *BMC Vet Res* 8: 162.
4. Martinez SA, Coronado GS (1997) Acquired conditions that lead to osteoarthritis in the dog. *Vet Clin North Am Small Anim Pract* 27: 759-775.
5. Valdes AM, Spector TD (2008) The contribution of genes to osteoarthritis. *Rheum Dis Clin North Am* 34: 581-603.
6. Perea S (2012) Nutritional management of osteoarthritis. *Compend Contin Educ Vet* 34: E4.
7. Loeser RF (2013) Aging processes and the development of osteoarthritis. *Curr Opin Rheumatol* 25: 108-113.
8. Arthritis Foundation (2013) Spotting arthritis in spot.
9. Elliot D (2007) Nutritional management of canine arthritis. *Veterinary Focus* 17: 43-48.
10. ASPCA (2013) Hip Dysplasia.
11. Hielm-Björkman AK, Kuusela E, Liman A, Markkola A, Saarto E, et al. (2003) Evaluation of methods for assessment of pain associated with chronic osteoarthritis in dogs. *J Am Vet Med Assoc* 222: 1552-1558.
12. Renberg WC (2005) Pathophysiology and management of arthritis. *Vet Clin North Am Small Anim Pract* 35: 1073-1091.
13. Gupta RC, Canerdy TD, Lindley J, et al. (2012) Comparative therapeutic efficacy and safety of type-II collagen (UC-II), glucosamine and chondroitin in arthritic dogs: pain evaluation by ground force plate. *J Anim Physiol Anim Nutri* 96: 770-777.
14. Osteoarthritis in Dogs (2012) Osteoarthritis in Dogs-Signs and Symptoms of Arthritis and Osteoarthritis.
15. Fahie MA, Ortolano GA, Guercio V, Schaffer JA, Johnston G, et al. (2013) A randomized controlled trial of the efficacy of autologous platelet therapy for the treatment of osteoarthritis in dogs. *J Am Vet Med Assoc* 243: 1291-1297.
16. Fleck A, Gupta RC, Goad JT, Lasher MA, Canerdy TD, et al. (2013) Anti-arthritic efficacy and safety of Crominex[®] 3+ (trivalent chromium, Phyllanthus emblica extract, and Shilajit) in moderately arthritic dogs. *J Vet Sci Anim Husb* 1: 1-8.
17. Dieppe PA, Lohmander LS (2005) Pathogenesis and management of pain in osteoarthritis. *Lancet* 365: 965-973.
18. Brandt KD, Dieppe P, Radin EL (2009) Etiopathogenesis of osteoarthritis. *Rheum Dis Clin North Am* 34: 531-559.
19. Leong DJ, Choudhury M, Hirsh DM, Hardin JA, Cobelli NJ, et al. (2013) Nutraceuticals: potential for chondroprotection and molecular targeting of osteoarthritis. *Int J Mol Sci* 14: 23063-23085.
20. Gupta RC (2015) Nutraceuticals in arthritis. In *Nutraceuticals: Efficacy, Safety and Toxicity*.
21. Muir HCS (1987) Pathological and biochemical changes in cartilage and other tissues of the canine knee resulting from induced joint instability. In: *Joint Loading: Biology and Health of Articular Structures*. Bristol, pp. 47-63.
22. Vaughan-Scott T, Taylor JH (1997) The pathophysiology and medical management of canine osteoarthritis. *J S Afr Vet Assoc* 68: 21-25.
23. Krasnokutsky S, Attur M, Palmer G, Samuels J, Abramson SB (2008) Current concepts in the pathogenesis of osteoarthritis. *Osteoarthritis Cartilage* 16: S1-3.
24. Abramson SB, Attur M (2009) Developments in the scientific understanding of osteoarthritis. *Arthritis Res Ther* 11: 227.
25. Sharma AR, Jagga S, Lee SS, Nam JS (2013) Interplay between cartilage and subchondral bone contributing to pathogenesis of osteoarthritis. *Int J Mol Sci* 14: 19805-19830.
26. Tonge DP, Pearson MJ, Jones SW (2014) The hallmarks of osteoarthritis and the potential to develop personalized disease-modifying pharmacological therapeutics. *Osteoarthr Cartil* 22: 609-621.

27. Gupta RC (Editor) Academic Press/Elsevier, Amsterdam, pp. 161-176.
28. Martinez SE, Chen Y, Ho EA, Martinez SA, Davies NM (2015) Pharmacological effects of a C-phycoyanin-based multicomponent nutraceutical in an in vitro canine chondrocyte model of osteoarthritis. *Can J Vet Res* 79: 241-249.
29. Rychel JK (2010) Diagnosis and treatment of osteoarthritis. *Top Companion Anim Med* 25: 20-25.
30. Lawley S, Gupta RC, Goad JT, Canerdy TD, Kalidindi SR (2013) Anti-inflammatory and anti-arthritic efficacy and safety of purified Shilajit in moderately arthritic dogs. *J Vet Sci Anim Husband* 1: 1-6.
31. Piscaer TM, Waarsing JH, Kops N, Pavljasevic P, Verhaar JA, et al. (2008) In vivo imaging of cartilage degeneration using microCT-arthrography. *Osteoarthritis Cartilage* 16: 1011-1017.
32. Kumar D, Wyatt CR, Lee S, Nardo L, Link TM, et al. (2013) Association of cartilage defects, and other MRI findings with pain and function in individuals with mild-moderate radiographic hip osteoarthritis and controls. *Osteoarthritis Cartilage* 21: 1685-1692.
33. Eckstein F, Guermazi A, Gold G, Duryea J, Hellio Le Graverand MP, et al. (2014) Imaging of cartilage and bone: promises and pitfalls in clinical trials of osteoarthritis. *Osteoarthritis Cartilage* 22: 1516-1532.
34. Roudebush P (2006) Pain management for canine osteoarthritis. *Proc North Am Vet Conf* 20: 1007-1010.
35. Rialland P, Bichot S, Lussier B, Moreau M, Beaudry F, et al. (2013) Effect of a diet enriched with green-lipped mussel on pain behavior and functioning in dogs with clinical osteoarthritis. *Can J Vet Res* 77: 66-74.
36. Pelletier JP, Caron JP, Evans C, Robbins PD, Georgescu HI, et al. (1997) In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. *Arthritis Rheum* 40: 1012-1019.
37. Fajardo M, Di Cesare PE (2005) Disease-modifying therapies for osteoarthritis: current status. *Drugs Aging* 22: 141-161.
38. Schoenherr WD (2005) Comprehensive nutritional management of canine osteoarthritis. *Proc North Am Vet Conf* 19: 783-784.
39. Sawaya S (2007) Physical and alternative therapies in the management of arthritic patients. *IVIS Vet Focus* 17: 37-42.
40. Sanderson RO, Beata C, Flipo RM, Genevois JP, Macias C, et al. (2009) Systematic review of the management of canine osteoarthritis. *Vet Rec* 164: 418-424.
41. Vilar JM, Batista M, Morales M, Santana A, Cuervo B, et al. (2014) Assessment of the effect of intraarticular injection of autologous adipose-derived mesenchymal stem cells in osteoarthritic dogs using a double blinded force platform analysis. *BMC Vet Res* 10: 143.
42. Moreau M, Dupuis J, Bonneau NH, Desnoyers M (2003) Clinical evaluation of a nutraceutical, carprofen and meloxicam for the treatment of dogs with osteoarthritis. *Vet Rec* 152: 323-329.
43. Lascelles BD, McFarland JM, Swann H (2005) Guidelines for safe and effective use of NSAIDs in dogs. *Vet Ther* 6: 237-251.
44. Dwivedi AK, Gurjar V, Kumar S, Singh N (2015) Molecular basis for nonspecificity of nonsteroidal anti-inflammatory drugs (NSAIDs). *Drug Discov Today* 20: 863-873.
45. Bergh MS, Budsberg SC (2005) The coxib NSAIDs: potential clinical and pharmacologic importance in veterinary medicine. *J Vet Intern Med* 19: 633-643.
46. Innes JF, Clayton J, Lascelles BD (2010) Review of the safety and efficacy of long-term NSAID use in the treatment of canine osteoarthritis. *Vet Rec* 166: 226-230.
47. Wolf G, Porth J, Stahl RA (2000) Acute renal failure associated with rofecoxib. *Ann Intern Med* 133: 394.
48. Hörl WH (2010) Nonsteroidal anti-inflammatory drugs and the kidney. *Pharmaceuticals* 3: 2291-2321.
49. Cheng HH, Chou CT, Sun TK, Liang WZ, Cheng JS, et al. (2015) Naproxen-induced Ca²⁺ movement and death in MDCK canine renal tubular cells. *Hum Exp Toxicol* 34: 1096-1105.
50. Lobetti RG, Joubert KE (2000) Effect of administration of nonsteroidal anti-inflammatory drugs before surgery on renal function in clinically normal dogs. *Am J Vet Res* 61: 1501-1507.
51. Sessions JK1, Reynolds LR, Budsberg SC (2005) In vivo effects of carprofen, deracoxib, and etodolac on prostanoid production in blood, gastric mucosa, and synovial fluid in dogs with chronic osteoarthritis. *Am J Vet Res* 66: 812-817.
52. Raekallio MR, Hielm-Björkman AK, Kejonen J, Salonen HM, Sankari SM (2006) Evaluation of adverse effects of long-term orally administered carprofen in dogs. *J Am Vet Med Assoc* 228: 876-880.
53. Coruzzi G, Venturi N, Spaggiari S (2007) Gastrointestinal safety of novel nonsteroidal antiinflammatory drugs: selective COX-2 inhibitors and beyond. *Acta Biomed* 78: 96-110.
54. Monteiro-Steagall BP, Steagall PV, Lascelles BD (2013) Systematic review of nonsteroidal anti-inflammatory drug-induced adverse effects in dogs. *J Vet Intern Med* 27: 1011-1019.
55. Barry S (2010) Non-steroidal anti-inflammatory drugs inhibit bone healing: a review. *Vet Comp Orthop Traumatol* 23: 385-392.
56. Lees P, Pelligand L, Elliott J, Toutain PL, Michels G, et al. (2015) Pharmacokinetics, pharmacodynamics, toxicology and therapeutics of mavacoxib in the dog: a review. *J Vet Pharmacol Ther* 38: 1-14.
57. Vandeweerdt JM, Coisson C, Clegg P, Cambier C, Pierson A, et al. (2012) Systematic review of efficacy of nutraceuticals to alleviate clinical signs of osteoarthritis. *J Vet Intern Med* 26: 448-456.
58. Comblain F, Serisier S, Barthelemy N, Balligand M, Henrotin Y, et al. (2015) Review of dietary supplements for the management of osteoarthritis in dogs in studies from 2004 to 2014. *J Vet Pharmacol Ther* .
59. Henrotin Y, Sanchez C, Balligand M (2005) Pharmaceutical and nutraceutical management of canine osteoarthritis: present and future perspectives. *Vet J* 170: 113-123.
60. Neil KM, Caron JP, Orth MW (2005) The role of glucosamine and chondroitin sulfate in treatment for and prevention of osteoarthritis in animals. *J Am Vet Med Assoc* 226: 1079-1088.
61. McCarthy G, O'Donovan J, Jones B, McAllister H, Seed M, et al. (2007) Randomised double-blind, positive-controlled trial to assess the efficacy of glucosamine/chondroitin sulfate for the treatment of dogs with osteoarthritis. *Vet J* 174: 54-61.
62. D'Altilio M, Peal A, Alvey M, Simms C, Curtsinger A, et al. (2007) Therapeutic Efficacy and Safety of Undenatured Type II Collagen Singly or in Combination with Glucosamine and Chondroitin in Arthritic Dogs. *Toxicol Mech Methods* 17: 189-196.
63. Boileau C, Martel-Pelletier J, Caron J, et al. (2009) Protective effects of total fraction of avocado/soybean unsaponifiables on the structural changes in experimental dog osteoarthritis: inhibition of nitric oxide synthase and matrix metalloproteinase-13. *Arthr Res Therap* 11: R41.
64. Hielm-Björkman A, Tulamo RM, Salonen H, Raekallio M (2009) Evaluating Complementary Therapies for Canine Osteoarthritis Part I: Green-lipped Mussel (*Perna canaliculus*). *Evid Based Complement Alternat Med* 6: 365-373.
65. Colitti M, Gaspario B, Della Pria A, Scaini C, Stefanon B (2012) Transcriptome modification of white blood cells after dietary administration of curcumin and non-steroidal anti-inflammatory drug in osteoarthritic affected dogs. *Vet Immunol Immunopathol* 147: 136-146.
66. Upadhyay A, Agrahari P, Singh DK (2014) A review on the pharmacological aspects of *Terminalia chebula*. *Int J Pharmacol* 10: 289-298.
67. Courties A, Gualillo O2, Berenbaum F3, Sellam J1 (2015) Metabolic stress-induced joint inflammation and osteoarthritis. *Osteoarthritis Cartilage* 23: 1955-1965.
68. Deligne C, Casulli S, Pigenet A, Bougault C, Campillo-Gimenez L, et al. (2015) Differential expression of interleukin-17 and interleukin-22 in inflamed and non-inflamed synovium from osteoarthritis patients. *Osteoarthritis Cartilage* 23: 1843-1852.
69. Greene MA, Loeser RF (2015) Aging-related inflammation in osteoarthritis. *Osteoarthritis Cartilage* 23: 1966-1971.
70. Liu-Bryan R (2015) Inflammation and intracellular metabolism: new targets in OA. *Osteoarthritis Cartilage* 23: 1835-1842.

71. Rogers EL, Reynard LN, Loughlin J (2015) The role of inflammation-related genes in osteoarthritis. *Osteoarthritis Cartilage* 23: 1933-1938.
72. Cheng HY, Lin TC, Yu KH, Yang CM, Lin CC (2003) Antioxidant and free radical scavenging activities of *Terminalia chebula*. *Biol Pharm Bull* 26: 1331-1335.
73. Na M, Bae K, Kang SS, Min BS, Yoo JK, et al. (2004) Cytoprotective effect on oxidative stress and inhibitory effect on cellular aging of *Terminalia chebula* fruit. *Phytother Res* 18: 737-741.
74. Lee HS, Won NH, Kim KH, Lee H, Jun W, et al. (2005) Antioxidant effects of aqueous extract of *Terminalia chebula* in vivo and in vitro. *Biol Pharm Bull* 28: 1639-1644.
75. Hazra B, Sarkar R, Biswas S, Mandal N (2010) Comparative study of the antioxidant and reactive oxygen species scavenging properties in the extracts of the fruits of *Terminalia chebula*, *Terminalia bellerica* and *Emblica officinalis*. *BMC Complement Altern Med* 10: 20.
76. Nair V, Singh S, Gupta YK (2010) Anti-arthritic and disease modifying activity of *Terminalia chebula* Retz. in experimental models. *J Pharm Pharmacol* 62: 1801-1806.
77. Pfundstein B, El Desouky SK, Hull WE, Haubner R, Erben G, et al. (2010) Polyphenolic compounds in the fruits of Egyptian medicinal plants (*Terminalia bellerica*, *Terminalia chebula* and *Terminalia horrida*): characterization, quantitation and determination of antioxidant capacities. *Phytochemistry* 71: 1132-1148.
78. Chang CL, Lin CS (2012) Phytochemical composition, antioxidant activity, and neuroprotective effect of *Terminalia chebula* Retzius extracts. *Evidence-Based Complement Alternat Med*.
79. Joonmoni L, Babul KB, Upama S (2012) Analgesic and antipyretic activities of *Terminalia chebula* Retz fruits extracts in experimental animals. *Int Res J Pharmaceut Appl Sci* 2: 159-163.
80. Seo JB, Jeong JY, Park JY, Jun EM, Lee SI, et al. (2012) Anti-Arthritic and Analgesic Effect of NDI10218, a Standardized Extract of *Terminalia chebula*, on Arthritis and Pain Model. *Biomol Ther (Seoul)* 20: 104-112.
81. Gaire BP, Jamarkattel-Pandit N, Lee D, Song J, Kim JY, et al. (2013) *Terminalia chebula* extract protects OGD-R induced PC12 cell death and inhibits I β s induced microglia activation. *Molecules* 18: 3529-3542.
82. Jami MS, Sultana Z, Ali ME, et al. (2014) Evaluation of analgesic and anti-inflammatory activities on ethanolic extract of *Terminalia chebula* fruits in experimental animals. *Am J Plant Sci* 5: 63-69.
83. Das ND, Jung KH, Park JH, Mondol MA, Shin HJ, et al. (2011) *Terminalia chebula* extract acts as a potential NF- κ B inhibitor in human lymphoblastic T cells. *Phytother Res* 25: 927-934.
84. Reddy DB, Reddy TC, Jyotsna G, Sharan S, Priya N, et al. (2009) Chebulagic acid, a COX-LOX dual inhibitor isolated from the fruits of *Terminalia chebula* Retz., induces apoptosis in COLO-205 cell line. *J Ethnopharmacol* 124: 506-512.
85. Barthakur NN, Arnold NP (1991) Nutritive value of the chebulinic myrobalan (*Terminalia chebula* Retz.) and its potential as a food source. *Food Chem* 40: 213-219.
86. Hamada S, Kataoka T, Woo JT, Yamada A, Yoshida T, et al. (1997) Immunosuppressive effects of gallic acid and chebulagic acid on CTL-mediated cytotoxicity. *Biol Pharm Bull* 20: 1017-1019.
87. Shivaprasad HN, Kharya MD, Rana AC, Mohan S (2006) Preliminary immunomodulatory activities of the aqueous extract of *Terminalia chebula*. *Pharmaceut Biol* 44: 32-34.
88. Aher V, Wahi AK (2011) Immunomodulatory activity of alcohol extract of *Terminalia chebula* Retz Combretaceae. *Trop J Pharmaceut Res* 10: 567-575.
89. Reddy VRC, Kumari SVR, Reddy BM, et al. (1990) Cardiotoxic activity of the fruit of *Terminalia chebula*. *Fitoterapia LXI*: 517-525.
90. Rao NK, Nammi S (2006) Antidiabetic and renoprotective effects of the chloroform extract of *Terminalia chebula* Retz. seeds in streptozotocin-induced diabetic rats. *BMC Complement Altern Med* 6: 17.
91. Gopi KS, Reddy AG, Jyothi K, Kumar BA (2010) Acetaminophen-induced Hepato- and Nephrotoxicity and Amelioration by Silymarin and *Terminalia chebula* in Rats. *Toxicol Int* 17: 64-66.
92. Kaur S, Jaggi RK (2010) Antinociceptive activity of chronic administration of different extracts of *Terminalia bellerica* Roxb. and *Terminalia chebula* Retz. fruits. *Indian J Exp Biol* 48: 925-930.
93. Larun L, Brurberg KG, Odgaard-Jensen J, Price JR (2015) Exercise therapy for chronic fatigue syndrome. *Cochrane Database Syst Rev* 2: CD003200.